Global gene expression analysis of canine osteosarcoma stem cells reveals a novel role for COX-2 in tumour initiation

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Pang, Lisa Y ^a   Gatenby, Emma L ^a   Kamida, Ayako ^a   Whitelaw, Bruce A ^a   Hupp, Ted R ^b   Argyle, David J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; MAVACOXIB; MELOXICAM; CYCLOOXYGENASE 2 INHIBITOR; DOXORUBICIN;

ADHERENT CELL; ANIMAL CELL; ARTICLE; CANCER INHIBITION; CANCER STEM CELL; CARCINOGENESIS; CELL INVASION; CELL ISOLATION; CELL MIGRATION; CELL TRANSFORMATION; CELL VIABILITY; CHEMOSENSITIVITY; COLONY FORMING UNIT; CONTROLLED STUDY; CYTOTOXICITY; DAUGHTER CELL; DOG; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOSARCOMA; OSTEOSARCOMA CELL; PROTEIN FUNCTION; THERAPY RESISTANCE; TRANSCRIPTION INITIATION; ANIMAL; ANIMAL DISEASE; BONE TUMOR; CELL DEATH; CELL SURVIVAL; DOG DISEASE; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MULTICELLULAR SPHEROID; PATHOLOGY; TUMOR INVASION;

ANIMALS; BONE NEOPLASMS; CARCINOGENESIS; CELL DEATH; CELL SURVIVAL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DOG DISEASES; DOGS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM INVASIVENESS; NEOPLASTIC STEM CELLS; OSTEOSARCOMA; SPHEROIDS, CELLULAR; TUMOR STEM CELL ASSAY;

EID: 84897397231     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083144     Document Type: Article

References (63)

1. Young JL Jr, Miller RW (1975) Incidence of malignant tumors in U. S. children. J Pediatr 86: 254-258.
2. Gatta G, Capocaccia R, Stiller C, Kaatsch P, Berrino F, et al. (2005) Childhood cancer survival trends in Europe: a EUROCARE Working Group study. J Clin Oncol 23: 3742-3751.
3. Fraumeni JF, Jr. (1967) Stature and malignant tumors of bone in childhood and adolescence. Cancer 20: 967-973.
4. Cotterill SJ, Wright CM, Pearce MS, Craft AW (2004) Stature of young people with malignant bone tumors. Pediatr Blood Cancer 42: 59-63. (Pubitemid 38173458)
5. Federman N, Bernthal N, Eilber FC, Tap WD (2009) The multidisciplinary management of osteosarcoma. Curr Treat Options Oncol 10: 82-93.
6. Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, et al. (2005) Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 23: 2004-2011. (Pubitemid 46211380)
7. Lewis IJ, Nooij MA, Whelan J, Sydes MR, Grimer R, et al. (2007) Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 99: 112-128.
8. Argyle DJ, Brearley MJ, Turek M (2008) Decision making in small animal oncology. Ames, Iowa: Blackwell Pub. Professional. xi, 390 p. p.
9. Pang LY, Argyle DJ (2009) Using naturally occurring tumours in dogs and cats to study telomerase and cancer stem cell biology. Biochim Biophys Acta 1792: 380-391.
10. Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, et al. (2005) A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 65: 9328-9337. (Pubitemid 41508000)
11. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, et al. (2008) Identification of cells initiating human melanomas. Nature 451: 345-349.
12. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, et al. (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63: 5821-5828. (Pubitemid 37187480)
13. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100: 3983-3988. (Pubitemid 36418143)
14. Bapat SA, Mali AM, Koppikar CB, Kurrey NK (2005) Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res 65: 3025-3029. (Pubitemid 40524578)
15. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65: 10946-10951. (Pubitemid 41713363)
16. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, et al. (2007) Identification and expansion of human colon-cancer-initiating cells. Nature 445: 111-115. (Pubitemid 46067311)
17. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, et al. (2008) Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 15: 504-514. (Pubitemid 351267301)
18. Blacking TM, Wilson H, Argyle DJ (2007) Is cancer a stem cell disease? Theory, evidence and implications. Vet Comp Oncol 5: 76-89.
19. Mueller F, Fuchs B, Kaser-Hotz B (2007) Comparative biology of human and canine osteosarcoma. Anticancer Res 27: 155-164. (Pubitemid 46370589)
20. Ek ET, Dass CR, Choong PF (2006) Commonly used mouse models of osteosarcoma. Crit Rev Oncol Hematol 60: 1-8. (Pubitemid 44349069)
21. Pang LY, Argyle D (2010) Cancer stem cells and telomerase as potential biomarkers in veterinary oncology. Vet J 185: 15-22.
22. Wilson H, Huelsmeyer M, Chun R, Young KM, Friedrichs K, et al. (2008) Isolation and characterisation of cancer stem cells from canine osteosarcoma. Vet J 175: 69-75. (Pubitemid 351176655)
23. Wang L, Park P, Lin CY (2009) Characterization of stem cell attributes in human osteosarcoma cell lines. Cancer Biol Ther 8: 543-552.
24. Levings PP, McGarry SV, Currie TP, Nickerson DM, McClellan S, et al. (2009) Expression of an exogenous human Oct-4 promoter identifies tumor-initiating cells in osteosarcoma. Cancer Res 69: 5648-5655.
25. Saini V, Hose CD, Monks A, Nagashima K, Han B, et al. (2012) Identification of CBX3 and ABCA5 as putative biomarkers for tumor stem cells in osteosarcoma. PLoS One 7: e41401.
26. Gibbs CP, Kukekov VG, Reith JD, Tchigrinova O, Suslov ON, et al. (2005) Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia 7: 967-976.
27. Fan TM (2010) Animal models of osteosarcoma. Expert Rev Anticancer Ther 10: 1327-1338.
28. Murray L, Chen B, Galy A, Chen S, Tushinski R, et al. (1995) Enrichment of human hematopoietic stem cell activity in the CD34+Thy-1+Lin- subpopulation from mobilized peripheral blood. Blood 85: 368-378.
29. Bj P, Tl G, Je V, Cw C, Jm B, et al. (2013) Prevalence of Endogenous CD34+ Adipose Stem Cells Predicts Human Fat Graft Retention in a Xenograft Model. Plast Reconstr Surg.
30. Chiou YS, Sang S, Cheng KH, Ho CT, Wang YJ, et al. (2013) Peracetylated (-)-epigallocatechin-3-gallate (AcEGCG) potently prevents skin carcinogenesis by suppressing the PKD1-dependent signaling pathway in CD34+ skin stem cells and skin tumors. Carcinogenesis 34: 1315-1322.
31. Gisina AM, Lupatov AY, Karalkin PA, Mainovskaya OA, Petrov LO, et al. (2012) Subpopulation of colorectal adenocarcinoma cells co-expressing CD133 and cancer stem cells markers of other tumors. Bull Exp Biol Med 152: 739-742.
32. Bardsley MR, Horvath VJ, Asuzu DT, Lorincz A, Redelman D, et al. (2010) Kitlow stem cells cause resistance to Kit/platelet-derived growth factor alpha inhibitors in murine gastrointestinal stromal tumors. Gastroenterology 139: 942-952.
33. Bozzi F, Conca E, Manenti G, Negri T, Brich S, et al. (2011) High CD133 expression levels in gastrointestinal stromal tumors. Cytometry B Clin Cytom 80: 238-247.
34. Chen YT, Chen WT, Huang WT, Wu CC, Chai CY (2012) Expression of MMP-2, MMP-9 and MMP-11 in dermatofibroma and dermatofibrosarcoma protuberans. Kaohsiung J Med Sci 28: 545-549.
35. Takahashi RH, Matsubayashi J, Yokotsuka M, Tachibana M, Kusama H, et al. (2012) An intrapelvic extraintestinal gastrointestinal stromal tumor of undetermined origin: diagnosis by prostate needle biopsy. Pathol Res Pract 208: 736-740.
36. Pan G, Thomson JA (2007) Nanog and transcriptional networks in embryonic stem cell pluripotency. Cell Res 17: 42-49. (Pubitemid 46096423)
37. Pang LY, Cervantes-Arias A, Else RW, Argyle DJ (2011) Canine Mammary Cancer Stem Cells are Radio- and Chemo- Resistant and Exhibit an Epithelial-Mesenchymal Transition Phenotype. Cancers 3: 1744-1762.
38. Hodgkiss-Geere HM, Argyle DJ, Corcoran BM, Whitelaw B, Milne E, et al. (2012) Characterisation and differentiation potential of bone marrow derived canine mesenchymal stem cells. Vet J 194: 361-368.
39. Basu-Roy U, Basilico C, Mansukhani A (2012) Perspectives on cancer stem cells in osteosarcoma. Cancer Lett.
40. Takemitsu H, Zhao D, Yamamoto I, Harada Y, Michishita M, et al. (2012) Comparison of bone marrow and adipose tissue-derived canine mesenchymal stem cells. BMC Vet Res 8: 150.
41. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, et al. (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8: 315-317. (Pubitemid 44269669)
42. Muzio G, Maggiora M, Paiuzzi E, Oraldi M, Canuto RA (2012) Aldehyde dehydrogenases and cell proliferation. Free Radic Biol Med 52: 735-746.
43. Christ O, Lucke K, Imren S, Leung K, Hamilton M, et al. (2007) Improved purification of hematopoietic stem cells based on their elevated aldehyde dehydrogenase activity. Haematologica 92: 1165-1172. (Pubitemid 350144173)
44. Ma I, Allan AL (2011) The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell Rev 7: 292-306.
45. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454: 436-444.
46. Wagemakers M, van der Wal GE, Cuberes R, Alvarez I, Andres EM, et al. (2009) COX-2 Inhibition Combined with Radiation Reduces Orthotopic Glioma Outgrowth by Targeting the Tumor Vasculature. Transl Oncol 2: 1-7.
47. Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, et al. (2009) The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 30: 377-386.
48. Naruse T, Nishida Y, Hosono K, Ishiguro N (2006) Meloxicam inhibits osteosarcoma growth, invasiveness and metastasis by COX-2-dependent and independent routes. Carcinogenesis 27: 584-592. (Pubitemid 43378898)
49. Dannhardt G, Ulbrich H (2001) In-vitro test system for the evaluation of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) inhibitors based on a single HPLC run with UV detection using bovine aortic coronary endothelial cells (BAECs). Inflamm Res 50: 262-269. (Pubitemid 32453012)
50. Mohammed SI, Khan KN, Sellers RS, Hayek MG, DeNicola DB, et al. (2004) Expression of cyclooxygenase-1 and 2 in naturally-occurring canine cancer. Prostaglandins Leukot Essent Fatty Acids 70: 479-483. (Pubitemid 38482611)
51. Mullins MN, Lana SE, Dernell WS, Ogilvie GK, Withrow SJ, et al. (2004) Cyclooxygenase-2 expression in canine appendicular osteosarcomas. J Vet Intern Med 18: 859-865. (Pubitemid 40081543)
52. Millanta F, Asproni P, Cancedda S, Vignoli M, Bacci B, et al. (2012) Immunohistochemical expression of COX-2, mPGES and EP2 receptor in normal and reactive canine bone and in canine osteosarcoma. J Comp Pathol 147: 153-160.
53. Duan DP, Dang XQ, Wang KZ, Wang YP, Zhang H, et al. (2012) The cyclooxygenase-2 inhibitor NS-398 inhibits proliferation and induces apoptosis in human osteosarcoma cells via downregulation of the survivin pathway. Oncol Rep 28: 1693-1700.
54. El-Badawi ZH, Muhammad EM, Noaman HH (2012) Role of immunohistochemical cyclo-oxygenase-2 (COX-2) and osteocalcin in differentiating between osteoblastomas and osteosarcomas. Malays J Pathol 34: 15-23.
55. Urakawa H, Nishida Y, Naruse T, Nakashima H, Ishiguro N (2009) Cyclooxygenase-2 overexpression predicts poor survival in patients with high-grade extremity osteosarcoma: a pilot study. Clin Orthop Relat Res 467: 2932-2938.
56. Singh B, Berry JA, Shoher A, Ayers GD, Wei C, et al. (2007) COX-2 involvement in breast cancer metastasis to bone. Oncogene 26: 3789-3796. (Pubitemid 46878131)
57. Kanojia D, Zhou W, Zhang J, Jie C, Lo PK, et al. (2012) Proteomic profiling of cancer stem cells derived from primary tumors of HER2/Neu transgenic mice. Proteomics 12: 3407-3415.
58. Singh B, Cook KR, Vincent L, Hall CS, Berry JA, et al. (2008) Cyclooxygenase-2 induces genomic instability, BCL2 expression, doxorubicin resistance, and altered cancer-initiating cell phenotype in MCF7 breast cancer cells. J Surg Res 147: 240-246.
59. Wolfesberger B, Walter I, Hoelzl C, Thalhammer JG, Egerbacher M (2006) Antineoplastic effect of the cyclooxygenase inhibitor meloxicam on canine osteosarcoma cells. Res Vet Sci 80: 308-316. (Pubitemid 43192713)
60. Cox SR, Liao S, Payne-Johnson M, Zielinski RJ, Stegemann MR (2011) Population pharmacokinetics of mavacoxib in osteoarthritic dogs. J Vet Pharmacol Ther 34: 1-11.
61. Busch U, Schmid J, Heinzel G, Schmaus H, Baierl J, et al. (1998) Pharmacokinetics of meloxicam in animals and the relevance to humans. Drug Metab Dispos 26: 576-584. (Pubitemid 28498364)
62. Zhang X, Morham SG, Langenbach R, Baggs RB, Young DA (2000) Lack of cyclooxygenase-2 inhibits growth of teratocarcinomas in mice. Exp Cell Res 254: 232-240. (Pubitemid 30080579)
63. Hong SH, Osborne T, Ren L, Briggs J, Mazcko C, et al. (2011) Protein kinase C regulates ezrin-radixin-moesin phosphorylation in canine osteosarcoma cells. Vet Comp Oncol 9: 207-218. Council